• Sandra Eder, Myriam Labopin, William Arcese, Reuven Or, Ignazio Majolino, Andrea Bacigalupo, Gennaro de Rosa, Liisa Volin, Dietrich Beelen, Hendrik Veelken, Nicolaas P M Schaap, Jurgen Kuball, Jan Cornelissen, Arnon Nagler, Mohamad Mohty, and Acute Leukemia Working Party.
• EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.
• Eur. J. Haematol. 2016 Jan 1; 96 (1): 90-7.

AbstractThiotepa is an alkylating compound with an antineoplastic and myeloablative activity and can mimic the effect of radiation. However, it is unknown whether this new regimen could safely replace the long-established ones. This retrospective matched-pair analysis evaluated the outcome of adults with acute myeloid leukaemia in first complete remission who received myeloablative conditioning either with a thiotepa-based (n = 121) or a cyclophosphamide/total body irradiation-based (TBI; n = 358) regimen for allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling or an unrelated donor. With a median follow-up of 44 months, the outcome was similar in both groups. Acute graft-versus-host disease grade II-IV was observed in 25% after thiotepa-containing regimen versus 35% after TBI (P = 0.06). The 2-yr cumulative incidence of chronic graft-versus-host disease was 40.5% for thiotepa and 41% for TBI (P = 0.98). At 2 yrs, the cumulative incidences of non-relapse mortality and relapse incidence were 23.9% (thiotepa) vs. 22.4% (TBI; P = 0.66) and 17.2% (thiotepa) vs. 23.3% (TBI; P = 0.77), respectively. The probabilities of leukaemia-free and overall survival at 2 yrs were not significantly different between the thiotepa and TBI groups, at 58.9% vs. 54.2% (P = 0.95) and 61.4% vs. 58% (P = 0.72), respectively. Myeloablative regimens using combinations including thiotepa can provide satisfactory outcomes, but the optimal conditioning remains unclear for the individual patient in this setting.© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

28 keywords...

hide…